缺血性脑血管病：回眸2022

doi:10.3969/j.issn.1673-5765.2023.02.001

摘要/Abstract

关键词: 脑血管病; 缺血性卒中; 无症状颈动脉狭窄; 硝酸甘油透皮贴剂; 抗凝治疗; 非心源性卒中; 干细胞; 单细胞图谱

王文洁, 吕书玉, 侯叶叶, 毛佳文, 韩颖, 李子孝. 缺血性脑血管病：回眸2022[J]. 中国卒中杂志, 2023, 18(02): 123-132.

WANG Wenjie, LYU Shuyu, HOU Yeye, MAO Jiawen, HAN Ying, LI Zixiao.

Highlights in Ischemic Cerebrovascular Diseases in 2022

[J]. Chinese Journal of Stroke, 2023, 18(02): 123-132.

[1] XIONG Y Y，GU H Q，ZHAO X Q，et al. Clinical characteristics and in-hospital outcomes of varying definitions of minor stroke：from a large-scale nation-wide longitudinal registry[J]. Stroke，2021，52（4）：1253-1258.
[2] VON WEITZEL-MUDERSBACH P，ANDERSEN G，HUNDBORG H H，et al. Transient ischemic attack and minor stroke are the most common manifestations of acute cerebrovascular disease：a prospective，population-based study—the Aarhus TIA study[J]. Neuroepidemiology，2013，40（1）：50-55.
[3] ZHANG C Q，ZHAO X Q，WANG C X，et al. Prediction factors of recurrent ischemic events in one year after minor stroke[J/OL]. PLoS One，2015，10（3）：e0120105[2023-01-30]. https://doi.org/10.1371/journal.pone.0120105.
[4] HAO Q K，TAMPI M，O'DONNELL M，et al. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack：systematic review and meta-analysis[J/OL]. BMJ（Clinical research ed），2018，363：k5108[2023-01-30]. https://doi.org/10.1136/bmj.k5108.
[5] COUTTS S B，HILL M D，CAMPOS C R，et al. Recurrent events in transient ischemic attack and minor stroke：what events are happening and to which patients?[J]. Stroke，2008，39（9）：2461-2466.
[6] AMARENCO PIERRE，LAVALLÉE PHILIPPA C，LABREUCHE JULIEN，et al. One-year risk of stroke after transient ischemic attack or minor stroke[J]. N Engl J Med，2016，374（16）：1533-1542.
[7] AMARENCO P，LAVALLéE P C，MONTEIRO TAVARES L，et al. Five-year risk of stroke after TIA or minor ischemic stroke[J]. N Engl J Med，2018，378（23）：2182-2190.
[8] HOBEANU C，LAVALLéE P C，CHARLES H，et al. Risk of subsequent disabling or fatal stroke in patients with transient ischaemic attack or minor ischaemic stroke：an international，prospective cohort study[J]. Lancet Neurol，2022，21（10）：889-898.
[9] CHRISTENSEN H. Long-term disability after transient ischaemic attack or minor stroke[J]. Lancet Neurol，2022，21（10）：859-860.
[10] FOSTER D S. Endarterectomy for asymptomatic carotid artery stenosis[J]. JAMA，1995，274（19）：1505.
[11] HALLIDAY A，HARRISON M，HAYTER E，et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis（ACST-1）：a multicentre randomised trial[J]. Lancet，2010，376（9746）：1074-1084.
[12] AMARENCO P，BOGOUSSLAVSKY J，CALLAHAN A 3rd，et al. High-dose atorvastatin after stroke or transient ischemic attack[J]. N Engl J Med，2006，355（6）：549-559.
[13] ABBOTT A L. Medical（nonsurgical） intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis：results of a systematic review and analysis[J/OL]. Stroke，2009，40（10）：e573-e583[2023-01-30]. https://doi.org/10.1161/STROKEAHA.109.556068.
[14] DEN HARTOG A G，ACHTERBERG S，MOLL F L，et al. Asymptomatic carotid artery stenosis and the risk of ischemic stroke according to subtype in patients with clinical manifest arterial disease[J]. Stroke，2013，44（4）：1002-1007.
[15] CHANG R W，TUCKER L Y，ROTHENBERG K A，et al. Incidence of ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，327（20）：1974-1982.
[16] STERPETTI A V，ARICI V，BOZZANI A. Ischemic stroke in patients with asymptomatic severe carotid stenosis without surgical intervention[J]. JAMA，2022，328（12）：1255-1256.
[17] HALLIDAY A，BULBULIA R，BONATI L H，et al. Second asymptomatic carotid surgery trial（ACST-2）：a randomised comparison of carotid artery stenting versus carotid endarterectomy[J]. Lancet，2021，398（10305）：1065-1073.
[18] LEONARDI-BEE J，BATH P M，PHILLIPS S J，et al. Blood pressure and clinical outcomes in the international stroke trial[J]. Stroke，2002，33（5）：1315-1320.
[19] GREENBERG S M，ZIAI W C，CORDONNIER C，et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2022，53（7）：e282-e361[2023-01-30]. https://doi.org/10.1161/STR.0000000000000407.
[20] WILLMOT M，GHADAMI A，WHYSALL B，et al. Transdermal glyceryl trinitrate lowers blood pressure and maintains cerebral blood flow in recent stroke[J]. Hypertension，2006，47（6）：1209-1215.
[21] WOODHOUSE L，SCUTT P，KRISHNAN K，et al. Effect of hyperacute administration（within 6 hours） of transdermal glyceryl trinitrate，a nitric oxide donor，on outcome after stroke：subgroup analysis of the efficacy of nitric oxide in stroke（ENOS） trial[J]. Stroke，2015，46（11）：3194-3201.
[22] RIGHT-2 INVESTIGATORS. Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke（RIGHT-2）：an ambulance-based，randomised，sham-controlled，blinded，phase 3 trial[J]. Lancet，2019，393（10175）：1009-1020.
[23] VAN DEN BERG S，UNIKEN VENEMA S，REININK H，et al. Prehospital transdermal glyceryl trinitrate in patients with presumed acute stroke（MR ASAP）：an ambulance-based，multicentre，randomised，open-label，blinded endpoint，phase 3 trial[J]. Lancet Neurol，2022，21（11）：971-981.
[24] MASOTTI L，GRIFONI E，DEI A，et al. Direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke：focus on real life studies[J]. J Thromb Thrombolysis，2019，47（2）：292-300.
[25] OLDGREN J，ASBERG S，HIJAZI Z，et al. Early versus delayed non-vitamin k antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation（TIMING）：a registry-based randomized controlled noninferiority study[J]. Circulation，2022，146（14）：1056-1066.
[26] POWERS W J，RABINSTEIN A A，ACKERSON T，et al. Guidelines for the early management of patients with acute ischemic stroke：2019 update to the 2018 guidelines for the early management of acute ischemic stroke：a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J/OL]. Stroke，2019，50（12）：e344-e418[2023-01-30]. https://doi.org/10.1161/STR.0000000000000211.
[27] KAM W，HOLMES D N，HERNANDEZ A F，et al. Association of recent use of non-vitamin k antagonist oral anticoagulants with intracranial hemorrhage among patients with acute ischemic stroke treated with alteplase[J]. JAMA，2022，327（8）：760-771.
[28] KLEINDORFER D O，TOWFIGHI A，CHATURVEDI S，et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J/OL]. Stroke，2021，52（7）：e364-e467[2023-01-30]. https://doi.org/10.1161/STR.0000000000000375.
[29] WANG Y J，WANG Y L，ZHAO X Q，et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med，2013，369（1）：11-19.
[30] JOHNSTON S C，EASTON J D，FARRANT M，et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA[J]. N Engl J Med，2018，379（3）：215-225.
[31] JOHNSTON S C，AMARENCO P，DENISON H，et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA[J]. N Engl J Med，2020，383（3）：207-217.
[32] SHARMA M，HART R G，CONNOLLY S J，et al. Stroke outcomes in the COMPASS trial[J]. Circulation，2019，139（9）：1134-1145.
[33] SHOAMANESH A，MUNDL H，SMITH E E，et al. Factor Ⅺa inhibition with asundexian after acute non-cardioembolic ischaemic stroke（PACIFIC-Stroke）：an international，randomised，double-blind，placebo-controlled，phase 2b trial[J]. Lancet，2022，400（10357）：997-1007.
[34] PICCINI J P，CASO V，CONNOLLY S J，et al. Safety of the oral factor Ⅺa inhibitor asundexian compared with apixaban in patients with atrial fibrillation（PACIFIC-AF）：a multicentre，randomised，double-blind，double-dummy，dose-finding phase 2 study[J]. Lancet，2022，399（10333）：1383-1390.
[35] GALE C，STATNIKOV Y，JAWAD S，et al. Neonatal brain injuries in England：population-based incidence derived from routinely recorded clinical data held in the National Neonatal Research Database[J/OL]. Arch Dis Child Fetal Neonatal Ed，2018，103（4）：F301-F306[2023-01-30]. https://doi.org/10.1136/archdischild-2017-313707.
[36] SORG A L，VON KRIES R，KLEMME M，et al. Incidence estimates of perinatal arterial ischemic stroke in preterm-and term-born infants：a national capture-recapture calculation corrected surveillance study[J]. Neonatology，2021，118（6）：727-733.
[37] GONZALEZ F，FERRIERO D M. Stem cells for perinatal stroke[J]. Lancet Neurol，2022，21（6）：497-499.
[38] WAGENAAR N，NIJBOER C H，VAN BEL F. Repair of neonatal brain injury：bringing stem cell-based therapy into clinical practice[J]. Dev Med Child Neurol，2017，59（10）：997-1003.
[39] BAAK LISANNE M，WAGENAAR NIENKE，VAN DER AA NIEK E et al. Feasibility and safety of intranasally administered mesenchymal stromal cells after perinatal arterial ischaemic stroke in the Netherlands（PASSIoN）：a first-in-human，open-label intervention study[J]. Lancet Neurol，2022，21（6）：528-536.
[40] GONZALEZ F，FERRIERO D M. Stem cells for perinatal stroke[J]. Lancet Neurol，2022，21（6）：497-499.
[41] WINKLER E A，KIM C N，ROSS J M，et al. A single-cell atlas of the normal and malformed human brain vasculature[J/OL]. Science，2022，375（6584）：eabi7377[2023-01-30]. https://doi.org/10.1126/science.abi7377.